Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 12/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486642 | 0.98 | P2RY6 (0.59) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL18486630 | 0.90 | P2RY2 (0.48) | P2RY2P2RY4P2RY6 | |
| SCHEMBL30697340 | 0.89 | P2RY2 (0.58) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL30874770 | 0.89 | P2RY6 (0.53) | P2RY2P2RY4P2RY6 | |
| SCHEMBL30423444 | 0.88 | P2RY2 (0.60) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8437841 | 0.87 | P2RY2 (0.59) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL607049 | 0.87 | POLA1 (0.60) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL30367562 | 0.87 | P2RY2 (0.57) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL38662148 | 0.87 | P2RY6 (0.56) | P2RY2P2RY4P2RY6 | |
| SCHEMBL8440926 | 0.87 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748451-A2 | ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2026-05-27 | — | — | EP | claimed |
| US-20230414649-A1 | ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMMICA (ES) | 2023-12-28 | — | — | US | claimed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | claimed |
| WO-2025217194-A1 | REPEAT DOSING OF RETROTRANSPOSONS | TYPEWRITER THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4429713-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | Translate Bio, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12048738-B2 | Composition for treating prostate cancer (PCa) | CureVac SE (DE) | 2024-07-30 | — | — | US | disclosed |
| CN-117795096-A | Methods, compositions and kits for preparing sequencing libraries | 吉复生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4291175-A1 | METHODS OF TREATING CANCERS USING STING AGONISTS | Dana-Farber Cancer Institute, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4225272-A1 | IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023086893-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | TRANSLATE BIO, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023014974-A1 | DOUBLE STRANDED MRNA VACCINES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| WO-2011069528-A1 | LYOPHILIZATION OF NUCLEIC ACIDS IN LACTATE-CONTAINING SOLUTIONS | CUREVAC GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010088927-A1 | USE OF PEI FOR THE IMPROVEMENT OF ENDOSOMAL RELEASE AND EXPRESSION OF TRANSFECTED NUCLEIC ACIDS, COMPLEXED WITH CATIONIC OR POLYCATIONIC COMPOUNDS | CUREVAC GMBH (DE) | 2010-08-12 | — | — | WO | disclosed |
| EP-2195015-A1 | COMPOSITION FOR TREATING PROSTATE CANCER (PCa) | Curevac GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009046975-A1 | COMPOSITION FOR TREATING PROSTATE CANCER (PCa) | CUREVAC GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| CN-1735693-A | Method for in vitro screening of 2' -substituted nucleic acids | ARCHEMIX CORP (US) | 2006-02-15 | — | — | CN | disclosed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | disclosed |
| US-5639653-A | ADMINISTERING MONOALKYL- OR ALKENYL-PYROPHOSPHATE TO MAMMAL TO STIMULATE LYMPHOCYTE CELL GROWTH AND ENHANCE IMMUNE RESPONSE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSTIY (US) | 1997-06-17 | — | — | US | disclosed |